Frequent loss of heterozygosity in two distinct regions, 8p23.1 and 8p22, in hepatocellular carcinoma

doi:10.3748/wjg.v13.i7.1090

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 7

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1978)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

248

HTML

1358

Figures (1-1)

185

Tables (1-3)

187

Sum=1978

Feb 21, 2007 (publication date) through Nov 15, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Feb 21, 2007; 13(7): 1090-1097
Published online Feb 21, 2007. doi: 10.3748/wjg.v13.i7.1090

Table 3 Distribution of LOH frequency at 8p in hepatocellular carcinoma cases by clinicopathological variables

ClinicopathologicalVariables	D8S264	D8S262	8p23.2	D8S1742	D8S277	D8S1819	D8S503	D8S1130	D8S552	D8S1109	8p23.1	D8S254	D8S261	D8S258	D8S298	8p22	D8S1752	D8S1734	D8S1445	8p21	8p23.2-21
Tumor size (mm)
> 50	0/4	0/4	0/5 (0%)	0/6	1/5	0/6	2/4	4/12	0/1	3/8	10/14 (71%)	4/10	0/5	3/7	1/6	6/13 (46%)	0/10	0/10	0/15	0/15 (0%)	10/15 (67%)
< 50	0/3	1/7	1/8 (13%)	3/11	3/11	2/6	3/7	5/11	3/6	1/9	6/17 (35%)	6/13	1/7	5/9	1/7	9/16 (56%)	3/11	2/14	1/15	4/15 (27%)	10/17 (59%)
Tumor number
St	0/2	0/3	0/5 (0%)	1/9	1/8	1/5	2/6	3/12	1/3	3/10	6/15 (41%)	9/18	1/6	4/7	1/7	4/13 (31%)	3/20	2/18	1/24	4/24 (17%)	17/24 (71%)
Mt	0/5	1/10	1/10 (10%)	2/7	3/8	1/6	3/6	6/11	2/4	1/7	10/16 (63%)	1/4	0/4	4/9	1/6	5/13 (38%)	0/2	0/5	0/7	0/7 (0%)	2/7 (29%)
Growth Pattern
Eg	0/8	1/13	1/15 (7%)	3/16	4/13	2/11	4/11	9/22	3/7	3/15	14/28 (50%)	8/20	1/8	7/14	2/13	13/26 (50%)	3/20	2/21	1/29	4/29 (14%)	18/29 (62%)
Ig	0/1	0/1	0/1 (0%)	0/1	0/3	0/2	1/1	0/1	0/0	1/2	2/5 (40%)	2/2	0/2	1/2	0/0	2/2 (100%)	0/2	0/2	0/2	0/2 (0%)	2/2 (100%)
Formation of capsule
Fc-	0/6	1/8	1/10 (10%)	2/3	1/4	1/4	2/3	4/7	3/4	2/5	5/6 (83%)	3/4	1/3	3/3	0/3	5/5 (100%)	2/5	1/5	0/5	2/5 (40%)	5/5 (100%)
Fc+	0/2	0/6	0/6 (0%)	1/14	3/12	1/8	3/9	5/17	0/3	2/12	11/25 (44%)	7/18	0/7	5/13	2/10	10/23 (43%)	1/18	1/18	1/26	2/26 (8%)	15/26 (58%)
Infiltration to capsule
Fc-Inf-	0/6	1/8	1/10 (10%)	1/5	1/7	0/7	3/5	3/8	0/4	2/8	7/11 (64%)	3/10	0/5	4/9	0/3	7/15 (47%)	1/10	1/12	0/15	1/15 (7%)	10/15 (67%)
Fc-Inf+	0/1	0/3	0/3 (0%)	1/8	1/3	0/2	1/4	3/10	0/0	1/5	5/13 (38%)	5/9	0/3	3/5	2/7	6/11 (55%)	1/10	0/8	0/13	1/13 (8%)	7/13 (54%)
Septal formation
Sf-	0/0	0/3	0/3 (0%)	1/7	2/6	1/7	3/5	3/8	1/4	2/5	7/13 (54%)	5/9	0/5	5/9	1/4	7/15 (47%)	1/12	0/12	0/16	1/16 (6%)	9/16 (56%)
Sf+	0/6	1/9	1/10 (10%)	2/8	1/5	0/3	1/4	3/10	1/1	2/7	5/12 (42%)	4/10	0/3	3/6	1/6	7/11 (64%)	2/9	1/9	0/12	2/12 (17%)	8/12 (67%)
Grading
WD	0/3	0/3	0/4 (0%)	1/4	2/4	2/4	1/2	4/6	1/4	1/2	4/8 (50%)	3/6	1/2	3/5	1/5	3/7 (43%)	1/7	1/7	1/7	2/7 (29%)	4/7 (57%)
MD	1/7	0/9	1/13 (8%)	2/13	2/12	1/9	4/12	5/17	1/12	3/6	11/21 (52%)	6/13	1/8	5/11	1/13	10/18 (56%)	2/12	1/13	0/21	2/21 (10%)	13/21 (62%)
PD	0/0	0/1	0/1 (0%)	0/1	0/3	0/1	0/1	1/3	2/3	0/1	2/3 (67%)	1/2	1/3	0/1	0/0	1/2 (50%)	0/2	0/2	0/2	0/2 (0%)	2/2 (100%)
pT
pT1	0/1	0/2	0/2 (0%)	0/2	0/1	0/1	0/1	1/2	0/3	0/2	0/5 (0%)	2/6	0/1	2/3	1/2	3/6 (50%)	0/6	0/6	0/6	0/6 (0%)	3/6 (50%)
pT2	1/7	0/7	1/10 (10%)	2/6	1/7	1/3	4/6	4/5	2/5	3/3	7/11 (64%)	5/8	1/4	5/7	0/4	7/11 (64%)	2/8	1/9	0/11	2/11 (18%)	8/11 (73%)
pT3	0/2	0/2	0/3 (0%)	1/4	2/2	1/3	0/2	3/8	1/5	0/1	5/8 (63%)	2/4	0/1	0/2	1/4	2/5 (40%)	1/5	1/5	1/8	2/8 (25%)	5/8 (63%)
pT4	0/0	0/0	0/0 (0%)	0/0	0/1	0/1	0/0	0/1	1/1	0/0	1/1 (100%)	1/1	0/2	0/0	0/0	1/2 (50%)	0/1	0/1	0/2	0/2 (0%)	1/2 (50%)
pN
pN-	1/8	0/10	1/12 (8%)	3/7	3/7	2/4	3/5	6/9	1/8	0/1	5/12 (42%)	4/9	0/0	6/7	2/7	8/13 (62%)	3/11	2/10	1/13	4/13 (31%)	9/13 (69%)
pNx	0/0	0/3	0/3 (0%)	0/6	1/5	0/4	1/4	2/9	2/6	1/5	6/12 (50%)	2/4	0/6	1/5	0/1	2/4 (50%)	0/5	0/5	0/7	0/7 (0%)	4/7 (57%)
pM
pM-	1/6	0/11	1/13 (8%)	2/7	1/5	1/2	3/5	3/10	3/8	2/4	6/14 (43%)	3/7	1/5	5/9	1/6	6/11 (55%)	2/10	1/11	0/13	2/13 (15%)	7/13 (54%)
pMx	0/0	0/0	0/0 (0%)	0/0	2/3	0/2	0/1	2/2	0/2	1/1	3/4 (75%)	5/6	0/1	0/1	0/0	5/7 (71%)	1/5	0/5	0/8	1/8 (13%)	7/8 (88%)
Vascular infiltration
V-	0/7	1/10	1/13 (8%)	2/10	3/10	1/8	4/9	6/13	2/6	2/9	9/20 (45%)	6/15	0/5	7/13	0/7	11/20 (55%)	2/16	2/18	1/21	3/21 (14%)	14/21 (67%)
V+	1/7	0/2	1/9 (11%)	1/7	1/6	1/4	1/3	3/10	1/1	2/8	7/11 (64%)	4/6	1/5	1/3	2/6	4/7 (57%)	1/6	0/5	0/9	1/9 (11%)	5/9 (56%)
Bile duct infiltration
B-	0/10	1/13	1/17 (6%)	3/18	4/15	2/11	4/13	10/24	3/9	3/17	15/28 (54%)	7/18	2/9	8/15	2/12	11/24 (46%)	2/19	2/20	1/27	3/27 (11%)	16/27 (59%)
B+	0/1	0/1	0/2 (0%)	0/3	0/3	1/4	1/3	0/4	1/3	1/4	3/4 (75%)	3/5	1/5	0/1	0/4	4/5 (80%)	1/4	0/4	0/5	1/5 (20%)	4/5 (80%)
Liver cirrhosis
LC-	0/2	0/6	0/6 (0%)	1/8	2/7	1/6	1/4	7/14	1/1	3/8	11/18 (61%)	6/11	0/4	4/7	2/8	9/16 (56%)	1/10	1/13	1/18	2/18 (11%)	12/18 (67%)
LC+	0/5	1/5	1/7 (14%)	2/9	2/9	1/6	4/8	2/9	2/6	1/9	5/13 (38%)	4/10	1/6	4/9	0/5	6/13 (46%)	2/11	1/11	0/14	2/14 (14%)	8/14 (57%)
Chronic hepatitis
CH-	0/1	0/3	0/4 (0%)	2/3	2/3	1/1	1/2	3/7	1/1	2/4	4/8 (50%)	4/6	1/3	2/5	1/3	5/7 (71%)	2/6	0/5	0/8	2/8 (25%)	6/8 (75%)
CH+	0/6	1/7	1/9 (11%)	1/13	2/13	1/11	4/9	6/16	2/6	2/13	12/23 (52%)	6/17	0/7	6/11	1/10	10/22 (45%)	1/17	2/19	1/24	2/24 (8%)	14/24 (58%)

Eg: expansive growth; Ig: infiltrative growth; St: solitary tumor; Mt: multiple tumor; LC: liver cirrhosis; CH: chronic hepatitis.

Citation: Lu T, Hano H, Meng C, Nagatsuma K, Chiba S, Ikegami M. Frequent loss of heterozygosity in two distinct regions, 8p23.1 and 8p22, in hepatocellular carcinoma. World J Gastroenterol 2007; 13(7): 1090-1097
URL: https://www.wjgnet.com/1007-9327/full/v13/i7/1090.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i7.1090